Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5FNI

Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination

Summary for 5FNI
Entry DOI10.2210/pdb5fni/pdb
Related5FNG 5FNH 5FNJ 5FNK 5FNL 5FNM
DescriptorCARBONIC ANHYDRASE 2, ZINC ION, GLYCEROL, ... (6 entities in total)
Functional Keywordslyase, fragments, carbonic anhydrase, metalloprotein
Biological sourceHOMO SAPIENS (HUMAN)
Total number of polymer chains1
Total formula weight29768.76
Authors
Woods, L.A.,Dolezal, O.,Ren, B.,Ryan, J.H.,Peat, T.S.,Poulsen, S.A. (deposition date: 2015-11-15, release date: 2016-03-02, Last modification date: 2024-01-10)
Primary citationWoods, L.,Dolezal, O.,Ren, B.,Ryan, J.H.,Peat, T.S.,Poulsen, S.
Native State Mass Spectrometry, Surface Plasmon Resonance and X-Ray Crystallography Correlate Strongly as a Fragment Screening Combination.
J.Med.Chem., 59:2192-, 2016
Cited by
PubMed Abstract: Fragment-based drug discovery (FBDD) is contingent on the development of analytical methods to identify weak protein-fragment noncovalent interactions. Herein we have combined an underutilized fragment screening method, native state mass spectrometry, together with two proven and popular fragment screening methods, surface plasmon resonance and X-ray crystallography, in a fragment screening campaign against human carbonic anhydrase II (CA II). In an initial fragment screen against a 720-member fragment library (the "CSIRO Fragment Library") seven CA II binding fragments, including a selection of nonclassical CA II binding chemotypes, were identified. A further 70 compounds that comprised the initial hit chemotypes were subsequently sourced from the full CSIRO compound collection and screened. The fragment results were extremely well correlated across the three methods. Our findings demonstrate that there is a tremendous opportunity to apply native state mass spectrometry as a complementary fragment screening method to accelerate drug discovery.
PubMed: 26882437
DOI: 10.1021/ACS.JMEDCHEM.5B01940
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.6 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon